Form 4: Cytosorbents COO Vincent Capponi Awarded Future Equity

Cytosorbents Corporation's President and COO, Vincent Capponi, was granted 89,100 restricted stock units and 111,100 stock options, effective August 8, 2025.

Summary

• Vincent Capponi, President and COO of Cytosorbents Corp (CTSO), was granted 89,100 restricted stock units (RSUs) and 111,100 stock options.
• The effective date for these grants is August 8, 2025.
• The 89,100 RSUs will vest in equal parts on the first and second year anniversaries of the grant date, contingent on continued service.
• The 111,100 stock options have an exercise price of $1.00 and will vest as to one-half on the first year anniversary, one-fourth on the second year, and one-fourth on the third year anniversary of the grant date, also subject to continued service.
• Following these transactions, Mr. Capponi will beneficially own 766,268 shares of common stock and 111,100 stock options.
• His total beneficial ownership of common stock includes 429,668 directly owned shares and various unvested RSUs from previous grants (10,100 from March 15, 2018; 17,900 from February 24, 2017; 54,000 from June 7, 2016; 125,000 from April 8, 2015) that vest upon a 'Change In Control,' plus 40,500 unvested RSUs from an April 2, 2024 grant.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally viewed positively as it aligns management's long-term interests with shareholder value creation and incentivizes retention.

Positives

• The grant of significant equity awards (89,100 RSUs and 111,100 stock options) to a key executive, Vincent Capponi, aligns management's interests with shareholder value creation.
• The vesting schedules for both RSUs (2 years) and stock options (3 years) promote long-term retention and performance incentives for the President and COO.
• The stock options have a low exercise price of $1.00, providing significant upside potential if the stock price appreciates.

Negatives

• The transaction date of August 8, 2025, is in the future, which is unusual for a Form 4 filing that typically reports past transactions. While such future-dated transactions can occur under Rule 10b5-1 plans, the corresponding checkbox on the form indicating a 10b5-1 plan was not marked.
• The RSUs were granted at a price of $0, which is typical for RSUs but represents potential future dilution if not offset by company performance.

Risks

• No specific risks related to company operations or financial health are mentioned in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

NA

Management Comments

• "I, Vincent Capponi, hereby make, constitute and appoint Peter J. Mariani, Chief Financial Officer of CytoSorbents Corporation (the Company), as well as any person holding the title of Chief Financial Officer of the Company, as my true and lawful attorney-in-fact to: (1) execute for and on my behalf, in my capacity as a director of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the Exchange Act); (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4, or 5, complete and execute any amendment(s) thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned."
• "The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 of the Exchange Act."

Industry Context

This filing is specific to executive compensation and insider ownership, not directly related to broader industry trends or competitive landscape. It reflects standard practices for incentivizing key executives in the biotechnology or medical device industry (assuming Cytosorbents' industry).

Comparison to Industry Standards

• The grant of RSUs and stock options to a President and COO is a common executive compensation practice across industries, including biotechnology and medical devices.
• The vesting schedules (2-3 years) are typical for long-term incentive plans, aiming to retain executives and align their interests with long-term company performance.
• The use of a Power of Attorney for SEC filings is standard practice for executives to ensure timely and compliant reporting.

Corporate Governance

Related Party Transactions

• The equity grants to Vincent Capponi, a key executive, represent a form of related party transaction (executive compensation).

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.
• Management: Provides significant long-term equity incentives and clarifies reporting responsibilities through the Power of Attorney.

Next Steps

• Vesting of 89,100 RSUs in equal parts on the first and second year anniversaries of August 8, 2025.
• Vesting of 111,100 stock options as to one-half on the first year anniversary, one-fourth on the second year, and one-fourth on the third year anniversary of August 8, 2025.
• Continued compliance with Section 16 of the Exchange Act for future transactions by Vincent Capponi, facilitated by the Power of Attorney.

Key Dates

Recommendation

This Form 4 filing primarily details executive compensation through equity grants. While the grants align executive interests with shareholders, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It's a standard compensation event.

Keywords

Cytosorbents Corp, CTSO, Vincent Capponi, insider transaction, Form 4, restricted stock units, RSUs, stock options, executive compensation, equity grant, corporate governance